<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="27881">Resveratrol</z:chebi> (3,4',5-trihydroxy-<z:chebi fb="0" ids="36007">trans-stilbene</z:chebi>), a polyphenolic natural product, shows chemopreventive properties against several <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart diseases</z:e>, <z:mp ids='MP_0001845'>inflammation</z:mp>, and <z:mp ids='MP_0001799'>viral</z:mp> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Epstein Barr virus (EBV), a γ-herpesvirus, contributes to the development of several human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> including Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we asked whether treatment with <z:chebi fb="0" ids="27881">resveratrol</z:chebi> would affect the viability of EBV-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells displaying different forms of latency </plain></SENT>
<SENT sid="3" pm="."><plain>We report here that <z:chebi fb="0" ids="27881">resveratrol</z:chebi>, regardless of EBV status, induces caspase-dependent <z:mpath ids='MPATH_3'>apoptosis</z:mpath> by arresting cell-cycle progression in G(1) phase </plain></SENT>
<SENT sid="4" pm="."><plain>However, <z:chebi fb="0" ids="27881">resveratrol</z:chebi> strongly induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in EBV(-) and latency I EBV(+) cells, whereas latency II and latency III EBV(+) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells showed a survival advantage that increased with the extent of the pattern of <z:mp ids='MP_0001799'>viral</z:mp> gene expression </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="27881">Resveratrol</z:chebi>-induced cell-cycle arrest and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> occurred in association with induction of p38 MAPK phosphorylation and suppression of ERK1/2 signaling pathway </plain></SENT>
<SENT sid="6" pm="."><plain>Moreover, NF-κB DNA-binding activity was inhibited in <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> lines except EBV(+) latency III cells </plain></SENT>
<SENT sid="7" pm="."><plain>LMP1 oncogene, which is expressed in latency III phenotype, is involved with the higher resistance to the antiproliferative effect of <z:chebi fb="0" ids="27881">resveratrol</z:chebi> because siRNA-mediated inhibition of LMP1 greatly increased the sensitivity of latency III <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells as well as that of lymphoblastoid cell lines to the <z:chebi fb="0" ids="26195">polyphenol</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>We propose that a combined <z:chebi fb="0" ids="27881">resveratrol</z:chebi>/siRNA strategy may be a novel approach for the treatment of EBV-associated B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> in which the <z:mp ids='MP_0001799'>viral</z:mp> pattern of gene expression has been defined </plain></SENT>
</text></document>